Dasatinib (Sprycel) is an inhibitor of the Src tyrosine kinase. This enzyme mediates signal transduction from the growth factor receptors to the downstream MAP kinase cascade. Blocking Src stops the meassage to grow that is sent from the growth factor to the cell nucleus. So the nuclear signals to grow are blocked by a Src inhibitor and this should have synergistic effects with total androgen ablation obtained with Zytiga.
The combination of Dasatinib and Zytiga represents a logical combination in the treatment of advanced prostate cancer and is currently undergoing clinical trials to test its safety and efficacy.
Molecular Structure of Dasatinib (Sprycel)
Molecular Structure of Abiraterone (Zytiga)
This looks like a good combination of drugs and we look forward to the results of the clinical trials.
No comments:
Post a Comment